Symic Bio Selected for “The Best of The Liver Meeting 2018” at AASLD

world news, trump, u.s., business news, stock market, entertainment news, business news, company news, market, commodities, commodity, Africa news

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]

SOURCE Symic Bio

SAN FRANCISCO, Nov. 9, 2018 /PRNewswire/ — Symic Bio, a biopharmaceutical company developing novel extracellular matrix targeting drugs, today announced that they were selected for “The Best of The Liver Meeting 2018” at the AASLD international liver meeting and will be presenting on its liver fibrosis program at the upcoming conference in San Francisco. Symic’s molecule, SBR-294, is unique in both its molecule class as well as in its approach to treating liver disease. 

SBR-294 is a matrix-targeting glycan therapeutic that is novel to Symic’s therapeutic platform. The molecule targets the platelet-axis of fibrosis, which is emerging as a key driver of liver fibrosis and disease progression. “Symic is targeting local wound healing by blocking platelet activation and thereby inhibition of fibrosis. This approached is binging a new MOA forward in the field,” said Morten Karsdal, CEO of Nordic Biosciences and fibrosis expert, who is also a coauthor on the work. Harsha Kabra, one of the lead scientists on the project at Symic, will be presenting results. 

Presentation details are as follows:


November 12th, 2018


2:00 p.m. Pacific Time


Moscone Center, Basic Science Session

About Symic Bio

Symic Bio is a biopharmaceutical company developing novel matrix-targeting therapeutics, a new category of therapeutics focused on matrix biology. These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules that play key regulatory roles within the extracellular matrix. Symic Bio currently has two clinical candidates: SB-061, directed at disease modification and pain management in the treatment of osteoarthritis, and SB-030, targeting the prevention of peripheral vein graft failure. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system. For additional information please visit the company’s website at, LinkedIn page at or follow on Twitter at

Cision View original content:

©2017 PR Newswire. All Rights Reserved.